A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs TAK 214 (Primary)
- Indications Norovirus infections
- Focus Pharmacodynamics
- Sponsors Takeda
- 11 Oct 2018 Planned number of patients changed from 800 to 575.
- 11 Oct 2018 Planned End Date changed from 30 Dec 2023 to 26 Oct 2021.
- 11 Oct 2018 Planned primary completion date changed from 30 Dec 2023 to 26 Oct 2021.